Efficacy and safety of minocycline in retinitis pigmentosa: a prospective, open-label, single-arm trial.

ABSTRACT: Retinitis pigmentosa (RP) is characterized by progressive photoreceptor cells death accelerated by the proliferation and activation of microglia pathologically. No consensus exists on the treatment. Minocycline is recognized as a microglia inhibitor with great anti-inflammatory and neuro-protective functions. However, efficacy of minocycline in RP patients is lacking. We conducted a prospective, open-label, and single-arm trial, in which daily oral minocycline of 100 mg was administered for 12 months in RP patients with light-adapted 30 Hz flicker electroretinography (ERG) amplitude >0 µV in at least one eye (NCT04068207). The primary outcome was the proportion of participants with improvement in the ERG amplitude at month 12. The secondary outcomes included improvements of the following i

SUBMITTER: Chen Y 

PROVIDER: S-EPMC11615376 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature